The pharmaceutical business in India has gained time but not certainty as a result of US President Donald Trump's most recent tariff declaration.
A phased tariff proposal for imported generic medications was presented by the US President on Wednesday. The plan offers producers a two-year window before implementing much higher charges. According to the plan, generic medications would remain duty-free in the US for two years starting on August 1. Following that, imports will be subject to a 100% tariff for a year before the tax jumps to 200%.
The announcement provides short-term respite for Indian pharmaceutical companies. However, it also marks the beginning of what may turn out to be one of the most significant strategic changes for the nation's pharmaceutical exporters in decades.The announcement provides short-term respite for Indian pharmaceutical companies. However, it also marks the beginning of what may turn out to be one of the most significant strategic changes for the nation's pharmaceutical exporters in decades.
The initiative is intended to support the Trump administration's larger effort to revive domestic manufacturing by pushing businesses to produce medications domestically rather than depending on foreign production.
Although there won't be much of an immediate impact on exports, Indian enterprises who have established their businesses around providing reasonably priced generic medications to the largest pharmaceutical market in the world may face significant long-term repercussions.Why is the US so important to India?
About 34% of India's pharmaceutical exports go to the United States, which is still the country's biggest pharmaceutical export market, according to the Department of Commerce. India exports pharmaceuticals to more than 200 nations, with more than 60% of shipments going to highly regulated markets like the US and Europe.
According to Commerce Secretary Rajesh Agrawal, India's pharmaceutical exports increased 9.4% year over year to $30.47 billion in 2024–2025 thanks to a manufacturing ecosystem that includes more than 3,000 businesses and 10,500 manufacturing facilities.

Separately, the US Food and Drug Administration (USFDA) reports that over 90% of US prescriptions are generic, highlighting the significance of the market for Indian pharmaceutical companies.
What has Trump suggested?
The goal of the proposed tariff pathway is to incentivize pharmaceutical businesses to set up production facilities in the United States.
As per the plan, there will be no tariffs on imported generic medications for two years starting on August 1. Imports will then be subject to a 200% levy following a 100% tax for a year.However, the laws pertaining to innovative and patented medications have not altered.
A two-year respite, but challenging choices lie ahead
The transition period provides Indian pharmaceutical companies with important time to reevaluate capital allocation, supply chains, and manufacturing plans.
Trump hasn't placed tariffs yet, so the immediate impact on exports is probably going to be minimal. However, if businesses continue to produce mostly from India, the anticipated increase in levies to 100% and eventually 200% could significantly change the economics of exporting generic medications to the US.
Industry executives have maintained, according to an ET report, that even though India's cost-effective manufacturing ecosystem is still globally competitive, long-term tariff barriers may push businesses to increase contract manufacturing partnerships or expand manufacturing capacity in the US in order to maintain market access.As a result, the policy changes the focus from tariffs alone to long-term manufacturing strategy.
Which Indian businesses might be affected?
Numerous well-known Indian pharmaceutical companies currently have production facilities in the US. Aurobindo Pharma, Dr. Reddy's Laboratories, Lupin, Cipla, and Zydus Lifesciences are a few of these companies that have established production facilities or activities in the nation.
If the tariff idea is carried out as announced, businesses with current US facilities may have more flexibility.
However, businesses like Alkem Laboratories and Torrent Pharmaceuticals continue to rely heavily on Indian production and earn comparatively little from US manufacturing activities.While Senores Pharma might profit from its local manufacturing presence serving the US generic market, Biocon still relies on manufacturing facilities in Malaysia and India for biosimilars and generic medications.
The path ahead
With Trump's declaration, India's pharmaceutical sector now has a defined transition period, something it did not have until Tuesday.
The two-year tariff-free window allows businesses to reconsider their investment plans and industrial footprints while also lessening the immediate danger to exports.
How quickly businesses adjust and whether manufacturing economics support a greater presence in the US will determine whether that is adequate.The next two years may define how a business that has spent decades transforming India into the world's pharmacy for reasonably priced generic medications serves its largest international market in the upcoming ten years.